Suppression of angiogenesis and tumor growth in vitro and in vivo using an anti‑angiopoietin‑2 single‑chain antibody

Zhang,Zhong-Lin; Zhang,Ji-Fa; Yuan,Yu-Feng; He,Yue-Ming; Liu,Quan‑Yan; Mao,Xiao-Wen; Ai,Yong-Biao; Liu,Zhi-Su

doi:10.3892/etm.2014.1476

Suppression of angiogenesis and tumor growth in vitro and in vivo using an anti‑angiopoietin‑2 single‑chain antibody

Authors:
- Zhong-Lin Zhang
- Ji-Fa Zhang
- Yu-Feng Yuan
- Yue-Ming He
- Quan‑Yan Liu
- Xiao-Wen Mao
- Yong-Biao Ai
- Zhi-Su Liu
View Affiliations

Affiliations: Hepatobiliary & Pancreatic Unit, Department of General Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of General Surgery, Branch Hospital in Fengxian of Shanghai No. 6 People's Hospital, Shanghai 201406, P.R. China
Published online on: January 7, 2014 https://doi.org/10.3892/etm.2014.1476
Pages: 543-552

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinomas (HCCs) are tumors with a highly developed vascular architecture. HCC cells require access to blood vessels for growth and metastasis; therefore, the inhibition of angiogenesis represents a potential therapeutic target for HCC that may reduce the mortality and morbidity from HCC. Various attempts to develop an anti‑angiogenic therapy have been made in past decades; however, modest results have been achieved in clinical trials and the challenge of HCC treatment remains. Single-chain antibodies (scFv) are characterized by low molecular weight, low immunogenicity, high penetration and a short half-life, and are easy to produce on a large scale by genetic engineering. Accordingly, an scFv against a specific angiogenic regulator, such as angiopoietin (Ang), may be a promising anti-angiogenic therapy for HCC. Our previous study indicated that an imbalanced expression of angiopoietin‑2 (Ang‑2) vs. angiopoietin‑1 (Ang‑1) in HCCs contributes to initiation of neovascularization and promotes the angiogenesis and progression of HCCs. Therefore, we suggest that specific Ang‑2‑targeting interventions may be valuable in the treatment of HCC via remodeling the neovascular network and changing the tumor microenvironment. In this study, a prokaryotic expression vector of Ang‑2 was constructed and purified human Ang‑2 protein was isolated. An scFv against human Ang‑2 (scFv-Ang2) was identified and purified via phage display technology, and the effects of scFv‑Ang2 in vitro and in vivo on HCC in nude mice were evaluated. The results show that scFv-Ang2 inhibits vascular endothelial growth factor (VEGF) and Ang‑2 induces the proliferation, migration and tubule formation of human umbilical vein endothelial cells (HUVECs) in vitro. In the in vivo assay, statistical indices, including tumor weight and volume, metastases to lungs, CD31 expression and the microvessel density (MVD) count in the scFv-Ang2-treated group of mice were significantly lower than those in the control group (P<0.05). In conclusion, the successfully generated scFv-Ang2 showed significant inhibitory effects on the angiogenesis and tumor growth of human HCC in vitro and in vivo.

View Figures

View References

1	Pisani P, Parkin DM, Bray F and Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 83:18–29. 1999. View Article : Google Scholar
2	D’Amato RJ, Loughnan MS, Flynn E and Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 91:4082–4085. 1994.
3	Farris AB III, Dursun N, Dhanasekaran R, Coban I, McIntosh EB, Adsay NV and Kim HS: Tumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapy. Pathol Res Pract. 208:15–21. 2012. View Article : Google Scholar : PubMed/NCBI
4	Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, Yen SH, Chang FY, Chan WK and Lee SD: Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol. 10:355–362. 2003. View Article : Google Scholar
5	Jeng KS, Sheen IS, Wang YC, Gu SL, Chu CM, Shih SC, Wang PC, Chang WH and Wang HY: Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J Gastroenterol. 10:643–646. 2004.
6	Poon RT, Ho JW, Tong CS, Lau C, Ng IO and Fan ST: Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 91:1354–1360. 2004. View Article : Google Scholar : PubMed/NCBI
7	Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
8	Eichholz A, Merchant S and Gaya AM: Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther. 3:69–82. 2010.PubMed/NCBI
9	Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX and Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 349:427–434. 2003. View Article : Google Scholar : PubMed/NCBI
10	Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD and Vassel A: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 30(5 Suppl 16): 117–124. 2003. View Article : Google Scholar : PubMed/NCBI
11	Mayer RJ: Two steps forward in the treatment of colorectal cancer. N Engl J Med. 350:2406–2408. 2004. View Article : Google Scholar : PubMed/NCBI
12	Desplancq D, Rinaldi AS, Stoessel A, Sibler AP, Busso D, Oulad-Abdelghani M, Van Regenmortel MH and Weiss E: Single-chain Fv fragment antibodies selected from an intrabody library as effective mono- or bivalent reagents for in vitro protein detection. J Immunol Methods. 369:42–50. 2011. View Article : Google Scholar
13	Yamaguchi R, Yano H, Nakashima Y, Ogasawara S, Higaki K, Akiba J, Hicklin DJ and Kojiro M: Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep. 7:725–729. 2000.PubMed/NCBI
14	Ochiumi T, Tanaka S, Oka S, Hiyama T, Ito M, Kitadai Y, Haruma K and Chayama K: Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma. Int J Oncol. 24:539–547. 2004.PubMed/NCBI
15	Sun XD, Liu XE, Wu JM, Cai XJ, Mou YP and Li JD: Expression and significance of angiopoietin-2 in gastric cancer. World J Gastroenterol. 10:1382–1385. 2004.PubMed/NCBI
16	Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O’Brien-Jenkins A, Randall TC, Rubin SC and Coukos G: Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res. 63:3403–3412. 2003.
17	Sfiligoi C, de Luca A, Cascone I, Sorbello V, Fuso L, Ponzone R, Biglia N, Audero E, Arisio R, Bussolino F, Sismondi P and De Bortoli M: Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer. 103:466–474. 2003. View Article : Google Scholar : PubMed/NCBI
18	Glade Bender J, Cooney EM, Kandel JJ and Yamashiro DJ: Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat. 7:289–300. 2004.PubMed/NCBI
19	Wong MP, Chan SY, Fu KH, Leung SY, Cheung N, Yuen ST and Chung LP: The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer. 29:11–22. 2000. View Article : Google Scholar : PubMed/NCBI
20	Zhang ZL, Liu ZS and Sun Q: Significance of angiopoietins, Tie2 and vascular endothelial growth factor in the angiogenesis and development of hepatocellular carcinoma. World J Gastroenterol. 12:4241–4245. 2006.PubMed/NCBI
21	Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN and Yancopoulos GD: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 277:55–60. 1997. View Article : Google Scholar : PubMed/NCBI
22	Dai H, Gao H, Zhao X, Dai L, Zhang X, Xiao N, Zhao R and Hemmingsen SM: Construction and characterization of a novel recombinant single-chain variable fragment antibody against White Spot Syndrome Virus from shrimp. J Immunol Methods. 279:267–275. 2003. View Article : Google Scholar : PubMed/NCBI
23	Barbas CF III, Burton DR, Scott JK and Silverman GJ: Phage Display: A Laboratory Manual. Cold Spring Harbor Laboratory Press; Cold Spring Harbor: 2001
24	Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
25	Gale NW and Yancopoulos GD: Growth factors acting via endothelia cell-spcific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev. 13:1055–1066. 1999. View Article : Google Scholar : PubMed/NCBI
26	Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC and Yancopoulos GD: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 87:1161–1169. 1996. View Article : Google Scholar : PubMed/NCBI
27	Saharinen P, Bry M and Alitalo K: How do angiopoietins Tie in with vascular endothelial growth factors? Curr Opin Hematol. 17:198–205. 2010.PubMed/NCBI
28	Pham VN, Roman BL and Weinstein BM: Isolation and expression analysis of three zebrafish angiopoietin genes. Dev Dyn. 221:470–474. 2001. View Article : Google Scholar : PubMed/NCBI
29	Hata K, Udagawa J, Fujiwaki R, Nakayama K, Otani H and Miyazaki K: Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer. Oncology. 62:340–348. 2002. View Article : Google Scholar : PubMed/NCBI
30	Mitsuhashi N, Shimizu H, Ohtsuka M, Wakabayashi Y, Ito H, Kimura F, Yoshidome H, Kato A, Nukui Y and Miyazaki M: Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology. 37:1105–1113. 2003. View Article : Google Scholar : PubMed/NCBI
31	Sugimachi K, Tanaka S, Taguchi K, Aishima S, Shimada M and Tsuneyoshi M: Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J Clin Pathol. 56:854–860. 2003. View Article : Google Scholar : PubMed/NCBI
32	Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN and Yancopoulos GD: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 87:1171–1180. 1996. View Article : Google Scholar : PubMed/NCBI
33	Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI, Master Z, Bendeck MP, Alitalo K, Dumont DJ, Yancopoulos GD and Stewart DJ: Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res. 49:659–670. 2001. View Article : Google Scholar : PubMed/NCBI
34	Wang J, Wu K, Zhang D, Tang H, Xie H, Hong L, Pan Y, Lan M, Hu S, Ning X and Fan D: Expression and clinical significances of angiopoietin-1, -2 and Tie2 in human gastric cancer. Biochem Biophy Res Commun. 337:386–393. 2005. View Article : Google Scholar : PubMed/NCBI
35	Nakayama T, Hatachi G, Wen CY, Yoshizaki A, Yamazumi K, Niino D and Sekine I: Expression and significance of Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: Immunohistochemical analysis and correlation with clinicopathological factors. World J Gastroenterol. 11:964–969. 2005. View Article : Google Scholar
36	Wada H, Nagano H, Yamamoto H, Yang Y, Kondo M, Ota H, Nakamura M, Yoshioka S, Kato H, Damdinsuren B, Tang D, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Sakon M, Dono K, Wakasa K and Monden M: Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int. 26:414–423. 2006. View Article : Google Scholar
37	Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
38	Smith GP: Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 228:1315–1317. 1985. View Article : Google Scholar : PubMed/NCBI
39	Smith GP and Petrenko VA: Phage Display. Chem Rev. 97:391–410. 1997. View Article : Google Scholar : PubMed/NCBI
40	Bratkovic T: Progress in phage display. Cell Mol Life Sci. 67:749–767. 2010. View Article : Google Scholar
41	Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotný J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, et al: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA. 85:5879–5883. 1988. View Article : Google Scholar : PubMed/NCBI
42	Rao Y, Zhong L, Liao T, Jin S, Wang Y, Song B, Li J, Zhang X, Hemmingsen SM, Xu Y and Dai H: Novel recombinant monoclonal antibodies for vitellogenin assays in cyprinid fish species. Dis Aquat Organ. 93:83–91. 2010. View Article : Google Scholar : PubMed/NCBI
43	Lobov IB, Brooks PC and Lang RA: Angiopoietin-2 displays VEGF-dependent modulations of capilliary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA. 99:11205–11210. 2002. View Article : Google Scholar : PubMed/NCBI
44	Ji Y, Wang Z, Li Z, Li K, Le X and Zhang T: Angiotensin II induces angiogenic factors production partly via AT1/JAK2/STAT3/SOCS3 signaling pathway in MHCC97H cells. Cell Physiol Biochem. 29:863–874. 2012. View Article : Google Scholar
45	Imai N, Hashimoto T, Kihara M, Yoshida S, Kawana I, Yazawa T, Kitamura H and Umemura S: Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest. 87:189–198. 2007. View Article : Google Scholar : PubMed/NCBI
46	White RR, Shan S, Rusconi CP, Shetty G, Dewhirst MW, Kontos CD and Sullenge BA: Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Aead Sci USA. 100:5028–5033. 2003. View Article : Google Scholar : PubMed/NCBI
47	Li Y, Tang Y, Ye L, Liu B, Liu K, Chen J and Xue Q: Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastisis-related genes through cDNA microarray. J Cancer Res Clin Oncol. 129:43–51. 2003.